Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Chimeric antigen receptor-macrophages: A new paradigm for cell therapy.

Created on 29 Oct 2026

Authors

Heng Wang, Yaling Li, Yiwei Shi, Yun Zhou, Guoping Zheng

Published in

Bioengineering & translational medicine. Volume 11. Issue 5. Pages e70157. Epub Jun 29, 2026.

Abstract

Chimeric antigen receptor (CAR) technology has propelled CAR-T cells to transformative success in hematologic malignancies, yet translation to solid tumors remains limited, motivating exploration of alternative CAR-engineered immune effectors. Macrophages, sentinels of the innate immune system, are abundantly recruited to solid tumors, making them compelling candidates. Preclinical studies show that CAR-engineered macrophages (CAR-M) exhibit precise tumor homing, potent antigen-directed phagocytosis, and the capacity to remodel immunosuppressive tumor microenvironments (TMEs). Notably, early-phase clinical investigations indicate a favorable safety profile, strengthening confidence in their therapeutic potential against solid cancers. In this review, we synthesize design principles for CAR-M constructs, with a particular focus on emerging engineering strategies for next-generation CAR-M. We further discuss their applications in oncology and emerging non-oncologic indications, and summarize the current clinical trial landscape. We further propose a "4S framework" (specificity, switchability, synergy, and safety) to guide next-generation CAR-M development. Collectively, these advances support CAR-M as a new paradigm for cancer therapy and beyond.

PMID:
42835939
Bibliographic data and abstract were imported from PubMed on 29 Oct 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 16
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement